Pluto Biosciences – a life sciences software-as-a-service (SaaS) platform – announced the closing of a $3.7 million seed round led by Silverton Partners. This funding round will fuel the expansion of Pluto’s innovative platform, which gives scientific teams both a unified home for managing their biological data, and an industry-first and interactive canvas for analyzing and visualizing complex biological data sets using no-code computational biology pipelines.
Since launching in 2021 from the Wyss Institute at Harvard University, Pluto has become a trusted partner for life sciences organizations in the US and UK, ranging in size and domain from academia to public biopharma. And with its biology-focused user experience, Pluto offers flexibility and ease of use when running bioinformatics analyses and creating plots, enabling researchers to focus on making groundbreaking discoveries and presenting them for maximum impact.
Currently, scientists use Pluto to accelerate biological applications spanning from preclinical and translational science research to cell and gene therapies, drug discovery and development, and clinical research. Designed to be flexible for the wide range of experiments a scientific team can perform, the platform can be used to analyze data from popular next-generation sequencing-based assays like RNA-seq, ChIP-seq, CUT&RUN, and CRISPR screens, and data from other workhorse assays for pharma and biotech including metabolomics, proteomics, biochemical assays, and animal behavioral studies. And the Pluto platform also integrates with sequencing services, electronic lab notebooks, project management platforms, and other collaboration tools. Pluto will use the funding to further build out the product and go-to-market teams, and develop advanced product features.
KEY QUOTES:
“Pluto is breaking down the obstacles that have traditionally prevented the widespread use of computational biology, including the need for compute infrastructure and black box ‘pipelines’, and empowering scientists to play an active role in their scientific discoveries. With Silverton Partners’ support, we will be able to increase sales velocity with the ultimate goal of transforming the way life sciences research is conducted.”
— Dr. Rani Powers, PhD, CEO and Founder of Pluto
“We were impressed by Pluto’s innovative product and ability to solve real needs currently slowing the pace of discovery in the life sciences industry. The platform’s seamless integration of data management, computational biology algorithms, and visualization capabilities sets it apart from competitors, and we believe the Company is poised for significant growth in the coming years.”
— Mike Dodd, General Partner at Silverton Partners
